An NRG Oncology/Gynecologic Oncology Group study of pegylated liposomal doxorubicin in combination with carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

Trial Profile

An NRG Oncology/Gynecologic Oncology Group study of pegylated liposomal doxorubicin in combination with carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Veliparib (Primary) ; Bevacizumab; Carboplatin; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Dec 2015 New trial record
    • 23 Nov 2015 Results of dose-escalation phase (n=27) published in the Gynecologic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top